Katsiki Niki, Kolovou Genovefa, Vrablik Michal
Department of Nutritional Sciences and Dietetics, International Hellenic University, 57400, Thessaloniki, Greece.
School of Medicine, European University Cyprus, 2404, Nicosia, Cyprus.
Curr Cardiol Rep. 2025 Jan 13;27(1):19. doi: 10.1007/s11886-024-02181-9.
In recent years, the terms "metabolic associated fatty liver disease-MAFLD" and "metabolic dysfunction-associated steatotic liver disease-MASLD" were introduced to improve the encapsulation of metabolic dysregulation in this patient population, as well as to avoid the negative/stigmatizing terms "non-alcoholic" and "fatty".
There is evidence suggesting links between MASLD and coronary heart disease (CHD), heart failure (HF), atrial fibrillation (AF), stroke, peripheral artery disease (PAD) and chronic kidney disease (CKD), although the data for HF, AF, stroke and PAD are scarcer. Physicians should consider the associations between MASLD and CV diseases in their daily practice. Based on this knowledge and current guidelines, they should also assess and manage CV risk/co-morbidities in such patients. It is important to further investigate the impact of MASLD on CV outcomes, a knowledge that will help to elucidate the clinical implications of this "novel" liver entity.
近年来，引入了“代谢相关脂肪性肝病-MAFLD”和“代谢功能障碍相关脂肪性肝病-MASLD”这两个术语，以更好地涵盖该患者群体的代谢失调情况，同时避免使用“非酒精性”和“脂肪性”等负面/污名化术语。
有证据表明MASLD与冠心病（CHD）、心力衰竭（HF）、心房颤动（AF）、中风、外周动脉疾病（PAD）和慢性肾脏病（CKD）之间存在关联，尽管关于HF、AF、中风和PAD的数据较少。医生在日常实践中应考虑MASLD与心血管疾病之间的关联。基于这些知识和当前指南，他们还应评估和管理此类患者的心血管风险/合并症。进一步研究MASLD对心血管结局的影响非常重要，这一知识将有助于阐明这种“新型”肝脏疾病的临床意义。
